Différences
Ci-dessous, les différences entre deux révisions de la page.
| Les deux révisions précédentes Révision précédente Prochaine révision | Révision précédente | ||
|
acupuncture:evaluation:oncologie:04. neuropathie peripherique induite par chimiotherapie [28 Aug 2025 19:05] Nguyen Johan [1.2.1.1. Yeh 2024] |
acupuncture:evaluation:oncologie:04. neuropathie peripherique induite par chimiotherapie [28 Aug 2025 19:06] (Version actuelle) Nguyen Johan [2. Overviews of Systematic Reviews] |
||
|---|---|---|---|
| Ligne 251: | Ligne 251: | ||
| - | ===== Overviews of Systematic Reviews ===== | ||
| Ligne 264: | Ligne 263: | ||
| ^Results| The outcomes were evaluated using data obtained from **14 SRs** that demonstrated moderate to high methodological and reporting quality. The findings showed that acupuncture (either alone or combined with electrical stimulation) and TEAS effectively alleviated CIPN symptoms, reduced CIPN pain, improved NCV, and enhanced quality of life.| | ^Results| The outcomes were evaluated using data obtained from **14 SRs** that demonstrated moderate to high methodological and reporting quality. The findings showed that acupuncture (either alone or combined with electrical stimulation) and TEAS effectively alleviated CIPN symptoms, reduced CIPN pain, improved NCV, and enhanced quality of life.| | ||
| ^Conclusion| The findings of this umbrella review indicate that these benefits were usually noticeable by the second week of treatment, persisted until the sixth week, and then gradually declined. Sensory nerve recovery occurred more rapidly than motor nerve recovery, often within 1.5 weeks. Although acupuncture combined with moxibustion or acupressure also enhanced patient outcomes, there was insufficient information available for further study analysis.| | ^Conclusion| The findings of this umbrella review indicate that these benefits were usually noticeable by the second week of treatment, persisted until the sixth week, and then gradually declined. Sensory nerve recovery occurred more rapidly than motor nerve recovery, often within 1.5 weeks. Although acupuncture combined with moxibustion or acupressure also enhanced patient outcomes, there was insufficient information available for further study analysis.| | ||
| + | |||
| + | |||
| + | ==== Ye 2025 ==== | ||
| + | |||
| + | Ye AL, Abdi S. Beyond p-values: a cross-sectional umbrella review of chemotherapy-induced peripheral neuropathy treatments. Front Pain Res (Lausanne). 2025 Mar 19;6:1564662. https://doi.org/10.3389/fpain.2025.1564662 | ||
| + | ^Introduction|Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of neurotoxic chemotherapy agents, significantly impacting the daily lives of many cancer survivors. Despite thousands of articles published on CIPN, we remain no closer to a successful treatment regimen for the condition. In recent years, several new clinical trials and systematic reviews have been published, many exploring nonpharmaceutical interventions, prompting the need for a comprehensive synthesis of this emerging evidence.| | ||
| + | ^Methods| We conducted an umbrella review to identify and appraise the **19 systematic reviews (SRs)** published in 2023 that examined randomized controlled trials (RCTs) for established CIPN treatment. We focused our analysis on the three most researched treatment options: oral drugs, exercise, and acupuncture. RCTs not previously synthesized together were reviewed, and effect size analyses were performed to allow readers to interpret the existing literature beyond binary p-values.| | ||
| + | ^Results| Our analysis of RCTs revealed the following key findings. For cancer survivors with CIPN after completing chemotherapy, serotonin-norepinephrine reuptake inhibitors (SNRIs) as well as **acupuncture** provided at least short-term relief for pain and sensory symptoms. For patients with CIPN who were actively undergoing chemotherapy, home-based balance and strength training exercises appeared to alleviate symptoms. Effect size analyses highlighted variability in treatment responses, underscoring the limitations of relying solely on p-values to assess intervention efficacy.| | ||
| + | ^Discussion|Through an umbrella review approach, we demonstrate that SRs are often less systematic than expected. None of the 19 SRs captured all relevant RCTs within their search timeframe. However, by cross-referencing SRs, we identified 41 RCTs across 42 publications, illustrating the feasibility of an umbrella review approach to uncover relevant trials. Furthermore, many SRs exhibited methodological concerns that limit the interpretability of their findings. Finally, we discuss multiple opportunities for refining methods and reporting in future CIPN treatment trials.| | ||
| ==== Shi 2023 ==== | ==== Shi 2023 ==== | ||
